Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study
Introduction: New anti-vascular endothelial growth factor (VEGF) treatments are emerging for the treatment of diabetic macular edema (DME)/neovascular age-related macular degeneration (nAMD). This study aimed to explore the treatment attributes patients find important when deciding on tre...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-01-01
|
| Series: | Ophthalmic Research |
| Online Access: | https://karger.com/article/doi/10.1159/000541349 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849727514711162880 |
|---|---|
| author | Alfredo García-Layana Gloria C. Chi Laurent Kodjikian Mariacristina Parravano David Chow Timothy L. Jackson Carl Danzig Liliana P. Paris Mirela Mirt Mickael Henry-Szatkowski Hannah B. Lewis Brittany Gentile |
| author_facet | Alfredo García-Layana Gloria C. Chi Laurent Kodjikian Mariacristina Parravano David Chow Timothy L. Jackson Carl Danzig Liliana P. Paris Mirela Mirt Mickael Henry-Szatkowski Hannah B. Lewis Brittany Gentile |
| author_sort | Alfredo García-Layana |
| collection | DOAJ |
| description |
Introduction: New anti-vascular endothelial growth factor (VEGF) treatments are emerging for the treatment of diabetic macular edema (DME)/neovascular age-related macular degeneration (nAMD). This study aimed to explore the treatment attributes patients find important when deciding on treatment options. Methods: This noninterventional survey study assessed treatment preferences through a discrete choice experiment (DCE) among patients with DME/nAMD in the USA, Canada, France, Italy, Spain, and the UK. The DCE design was informed by a targeted literature review and qualitative interview research and included five treatment attributes: mode of administration, frequency of examinations, frequency of injections or refills, likely change in visual acuity, and eye-related side effects. Conditional logit models were used to analyze the choice data. Results: Overall, 537 patients completed the DCE (DME, n = 173; nAMD, n = 364). Patients reported preferring “injection” over “implant surgery and refills” and better visual outcomes over “stabilization,” which were also the most important attributes driving preference (35.1% and 31.5%, respectively). They also showed a preference for less-frequent treatment and examinations and for “mild-moderate, frequent” over “severe, rare” side effects. These findings were generally consistent across the two conditions, although significant differences were found depending on anti-VEGF treatment duration (nAMD, DME) and number of reported barriers (nAMD). Conclusion: Patient preferences for treatment are driven by several factors. Considering these preferences is essential when designing/introducing new therapies. Individual treatment preferences should be identified and given key consideration when helping patients select from an expanding array of treatment options. |
| format | Article |
| id | doaj-art-6e4a00498fa04bf286c0a995a62ca7da |
| institution | DOAJ |
| issn | 1423-0259 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Ophthalmic Research |
| spelling | doaj-art-6e4a00498fa04bf286c0a995a62ca7da2025-08-20T03:09:48ZengKarger PublishersOphthalmic Research1423-02592025-01-01681132210.1159/000541349Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment StudyAlfredo García-LayanaGloria C. ChiLaurent Kodjikianhttps://orcid.org/0000-0002-3908-6716Mariacristina ParravanoDavid ChowTimothy L. JacksonCarl DanzigLiliana P. ParisMirela MirtMickael Henry-SzatkowskiHannah B. LewisBrittany Gentile Introduction: New anti-vascular endothelial growth factor (VEGF) treatments are emerging for the treatment of diabetic macular edema (DME)/neovascular age-related macular degeneration (nAMD). This study aimed to explore the treatment attributes patients find important when deciding on treatment options. Methods: This noninterventional survey study assessed treatment preferences through a discrete choice experiment (DCE) among patients with DME/nAMD in the USA, Canada, France, Italy, Spain, and the UK. The DCE design was informed by a targeted literature review and qualitative interview research and included five treatment attributes: mode of administration, frequency of examinations, frequency of injections or refills, likely change in visual acuity, and eye-related side effects. Conditional logit models were used to analyze the choice data. Results: Overall, 537 patients completed the DCE (DME, n = 173; nAMD, n = 364). Patients reported preferring “injection” over “implant surgery and refills” and better visual outcomes over “stabilization,” which were also the most important attributes driving preference (35.1% and 31.5%, respectively). They also showed a preference for less-frequent treatment and examinations and for “mild-moderate, frequent” over “severe, rare” side effects. These findings were generally consistent across the two conditions, although significant differences were found depending on anti-VEGF treatment duration (nAMD, DME) and number of reported barriers (nAMD). Conclusion: Patient preferences for treatment are driven by several factors. Considering these preferences is essential when designing/introducing new therapies. Individual treatment preferences should be identified and given key consideration when helping patients select from an expanding array of treatment options. https://karger.com/article/doi/10.1159/000541349 |
| spellingShingle | Alfredo García-Layana Gloria C. Chi Laurent Kodjikian Mariacristina Parravano David Chow Timothy L. Jackson Carl Danzig Liliana P. Paris Mirela Mirt Mickael Henry-Szatkowski Hannah B. Lewis Brittany Gentile Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study Ophthalmic Research |
| title | Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study |
| title_full | Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study |
| title_fullStr | Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study |
| title_full_unstemmed | Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study |
| title_short | Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study |
| title_sort | patient preferences with anti vascular endothelial growth factor treatment for neovascular age related macular degeneration and diabetic macular edema a multinational discrete choice experiment study |
| url | https://karger.com/article/doi/10.1159/000541349 |
| work_keys_str_mv | AT alfredogarcialayana patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy AT gloriacchi patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy AT laurentkodjikian patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy AT mariacristinaparravano patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy AT davidchow patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy AT timothyljackson patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy AT carldanzig patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy AT lilianapparis patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy AT mirelamirt patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy AT mickaelhenryszatkowski patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy AT hannahblewis patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy AT brittanygentile patientpreferenceswithantivascularendothelialgrowthfactortreatmentforneovascularagerelatedmaculardegenerationanddiabeticmacularedemaamultinationaldiscretechoiceexperimentstudy |